AMRS Stock Recent News
AMRS LATEST HEADLINES
Amyris, Inc. (NASDAQ: AMRS) is a small-cap company with a market cap of just over $381 million at the time of this writing. And the stock is a legitimate penny stock, with shares trading just over the $1 mark in early morning trading on April 17, 2023.
Amyris (AMRS) and Givaudan collaborate to leverage the former's technological platform for designing, scaling and manufacturing the best-performing bio-fermented ingredients.
Record revenues in the Consumer segment drive Amyris' (AMRS) top line in the fourth quarter.
Amyris, Inc. (NASDAQ:AMRS ) Q4 2022 Earnings Conference Call March 15, 2023 4:30 PM ET Company Participants Han Kieftenbeld - Chief Financial Officer John Melo - President and Chief Executive Officer Eduardo Alvarez - Chief Operating Officer Conference Call Participants Colin Rusch - Oppenheimer Rachel Vatnsdal - JPMorgan Korinne Wolfmeyer - Piper Sandler Steven Mah - Cowen and Co. Sameer Joshi - H.C. Wainwright Laurence Alexander - Jefferies Operator Welcome to the Amyris Fourth Quarter 2022 Financial Results Conference Call.
Amyris, Inc. (AMRS) delivered earnings and revenue surprises of -160% and 27.18%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Uncertainty still surrounds the strategic transaction, but it is still likely to close in the coming weeks. Amyris' cash flow problems are improving rapidly, but a large amount of outside cash will likely still be needed to reach profitability.
Biotech penny stocks to watch right now. The post 3 Top Biotech Penny Stocks Under $3 To Watch Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Amyris is on the cusp of closing a record strategic transaction slated to generate ~$500mm in cash value. All indications point to a transaction closing in the next two to three weeks.
To say that the company had a third quarter to forget is quite the understatement.
Amyris, Inc. (AMRS) delivered earnings and revenue surprises of -109.52% and 36.48%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?